NeuroBo Pharmaceuticals, Inc. (NRBO)


+1.17 (+9.35%)
Symbol NRBO
Price $13.69
Beta -0.381
Volume Avg. 0.54M
Market Cap 12.167M
Shares () -
52 Week Range 7.41-77.4
1y Target Est -
DCF Unlevered NRBO DCF ->
DCF Levered NRBO LDCF ->
ROE -240.32% Strong Sell
ROA -247.20% Strong Sell
Operating Margin -
Debt / Equity 14.14% Neutral
P/E -
P/B 1.38 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest NRBO news

Mr. Jeong Gu Kang
NASDAQ Capital Market

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. It develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.